Psychopharmacologic treatment of personality disorders;Psychopharmakologische behandlung von und bei persönlichkeitsstö rungen

Fortschritte der Neurologie Psychiatrie

Volumn 76, Issue 3, 2008, Pages 139-148

  Quante, Arnim ^a   Ropke S ^a   Merkl, A ^a   Anghelescu, I ^a   Lammers, C H ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Antidepressives; Atypical neuroleptics; Personality disorder; Psychopharmacotherapy

Indexed keywords

ANTICONVULSIVE AGENT; ARIPIPRAZOLE; BENZODIAZEPINE; CITALOPRAM; CLONAZEPAM; CLONIDINE; CLOZAPINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LAMOTRIGINE; METHYLPHENIDATE; MIRTAZAPINE; MODAFINIL; MONOAMINE OXIDASE INHIBITOR; MOOD STABILIZER; NEUROLEPTIC AGENT; OLANZAPINE; OMEGA 3 FATTY ACID; OXCARBAZEPINE; PLACEBO; QUETIAPINE; REBOXETINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; PSYCHOTROPIC AGENT;

AGGRESSION; ANXIETY DISORDER; ARTICLE; BORDERLINE STATE; CLINICAL PRACTICE; CLINICAL TRIAL; COMORBIDITY; DEPRESSION; DISEASE CLASSIFICATION; DISSOCIATION; DRUG USE; HUMAN; IMPULSIVENESS; PARANOIA; PERSONALITY DISORDER; PSYCHOLOGICAL ASPECT; PSYCHOPHARMACOLOGY; PSYCHOSIS; SCHIZOIDISM; SYMPTOM CHECKLIST 90; TREATMENT INDICATION; REVIEW;

HUMANS; PERSONALITY DISORDERS; PSYCHOTROPIC DRUGS;

EID: 44449095204     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-996179     Document Type: Article

References (72)

1. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (3rd edition). Washington, DC: American Psychiatric Association. APA. 1980
2. Links PS, Boggild A, Sarin N. Psychopharmacology of personality disorders: review and emerging issues. Curr Psychiatry Rep 2001; 3: 70-76
3. Cloninger CR. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiatry 1987; 44: 373-588
4. Soloff PH. Algorithms for pharmacological treatment of personality dimensions: symptom-specific treatments for cognitive-perceptual, affective, and impulsive-behavioral dysregulation. Bull Menninger Clin 1998; 62: 195-214
5. Links PS, Steiner M. Psychopharmacologic management of patients with borderline personality disorder. Can J Psychiatry 1988; 33: 355-359
6. Soloff PH. Psychopharmacology of borderline personality disorder. Psychiatr Clin North Am 2000; 23: 169-92, ix
7. Paris J. Recent advances in the treatment of borderline personality disorder. Can J Psychiatry 2005; 50: 435-441
8. Olivier B, Mos J, Oorschot R van, Hen R. Serotonin receptors and animal models of aggressive behavior. Pharmacopsychiatry 1995; 28 Suppl 2: 80-90
9. Sass H, Jünemann K. Affective disorders, personality and personality disorders. Acta Psychiatr Scand Suppl 2003; 418: 34-40
10. Saß H. Diagnostische Kriterien DSM-IV-TR. Wittchen, H.U. Zaudig M. Houben I, 2000. Ref Type: Generic
11. Kendler KS, Masterson CC, Davis KL. Psychiatric illness in first-degree relatives of patients with paranoid psychosis, schizophrenia and medical illness. Br J Psychiatry 1985; 147: 524-531
12. Moller HJ. Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003; 17: 793-823
13. Tsuang MT, Stone WS, Faraone SV. Schizophrenia: a review of genetic studies. Harv Rev Psychiatry 1999; 7: 185-207
14. Kendler KS, McGuire M, Gruenberg AM, O'Hare A, Spellman M, Walsh D. The Roscommon Family Study. III. Schizophrenia-related personality disorders in relatives. Arch Gen Psychiatry 1993; 50: 781-788
15. Kety SS. Mental illness in the biological and adoptive relatives of schizophrenic adoptees: findings relevant to genetic and environmental factors in etiology. Am J Psychiatry 1983; 140: 720-727
16. Siever LJ, Davis KL. The pathophysiology of schizophrenia disorders: perspectives from the spectrum. Am J Psychiatry 2004; 161: 398-413
17. Fenron WS, McGlashan TH. Risk of schizophrenia in character disordered patients. Am J Psychiatry 1989; 146: 1280-1284
18. Hoch PH, Cattell JP, Strahl MO, Pennes HH. The course and outcome of pseudoneurotic schizophrenia. Am J Psychiatry 1962; 119: 106-115
19. Coccaro EF. Clinical outcome of psychopharmacologic treatment of borderline and schizotypal personality disordered subjects. J Clin Psychiatry 1998; 59 Suppl 1: 30-35
20. Jensen HV, Andersen J. An open, noncomparative study of amoxapine in borderline disorders. Acta Psychiatr Scand 1989; 79: 89-93
21. Frankenburg FR, Zanarini MC. Clozapine treatment of borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402-405
22. Serban G, Siegel S. Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol. Am J Psychiatry 1984; 141: 1455-1458
23. Hymowitz P, Frances A, Jacobsberg LB, Sickles M, Hoyt R. Neuroleptic treatment of schizotypal personality disorders. Compr Psychiatry 1986; 27: 267-271
24. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52: 13-19
25. Koenigsberg HW, Reynolds D, Goodman M et al. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003; 64: 628-634
26. Salzman C, Wolfson AN, Schatzberg A et al. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995; 15: 23-29
27. Kavoussi RJ, Liu J, Coccaro EF. An open trial of sertraline in personality disordered patients with impulsive aggression. J Clin Psychiatry 1994; 55: 137-141
28. Torgersen T, Gjervan B, Rasmussen K. ADHD in adults: a study of clinical characteristics, impairment and comorbidity. Nord J Psychiatry 2006; 60: 38-43
29. Widiger TA, Weissman MM. Epidemiology of borderline personality disorder. Hosp Community Psychiatry 1991; 42: 1015-1021
30. Schmahl C, Bohus M. [Symptom-focussed drug therapy in borderline personality disorder]. Fortschr Neurol Psychiatr 2001; 69: 310-321
31. Skodol AE, Oldham JM, Gallaher PE. Axis II comorbidity of substance use disorders among patients referred for treatment of personality disorders. Am J Psychiatry 1999; 156: 733-738
32. Zanarini MC, Frankenburg FR, Hennen J, Reich DB, Silk KR. Axis I comorbidity in patients with borderline personality disorder: 6-year follow-up and prediction of time to remission. Am J Psychiatry 2004; 161: 2108-2114
33. Markovitz PJ, Calabrese JR, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991; 148: 1064-1067
34. Reist C, Nakamura K, Sagart E, Sokolski KN, Fujimoto KA. Impulsive aggressive behavior: open-label treatment with citalopram. J Clin Psychiatry 2003; 64: 81-85
35. Markovitz PJ, Wagner SC. Venlafaxine in the treatment of borderline personality disorder. Psychopharmacol Bull 1995; 31: 773-777
36. Anghelescu I, Janen B, Schindler F, Lammers CH. Worsening of borderline symptoms under reboxetine treatment. J Neuropsychiatry Clin Neurosci 2005; 17: 559-560
37. Soloff PH, George A, Nathan RS, Schulz PM, Perel JM. Paradoxical effects of amitriptyline on borderline patients. Am J Psychiatry 1986; 143: 1603-1605
38. Bellino S, Paradiso E, Bogetto F. Oxcarbazepine in the treatment of borderline personality disorder: a pilot study. J Clin Psychiatry 2005; 66: 1111-1115
39. Stanford MS, Helfritz LE, Conklin SM et al. A comparison of anticonvulsants in the treatment of impulsive aggression. Exp Clin Psychopharmacol 2005; 13: 72-77
40. Nickel MK, Nickel C, Kaplan P et al. Treatment of aggression with topiramate in male borderline patients: a double-blind, placebo-controlled study. Biol Psychiatry 2005; 57: 495-499
41. Soloff PH, Cornelius J, George A, Nathan S, Perel JM, Ulrich RF. Efficacy of phenelzine and haloperidol in borderline personality disorder. Arch Gen Psychiatry 1993; 50: 377-385
42. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998; 59: 103-107
43. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine-fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004; 65: 903-907
44. Soler J, Pascual JC, Campins J et al. Double-blind, placebo-controlled study of dialectical behavior therapy plus olanzapine for borderline personality disorder. Am J Psychiatry 2005; 162: 1221-1224
45. Rocca P, Marchiaro L, Cocuzza E, Bogetto F. Treatment of borderline personality disorder with risperidone. J Clin Psychiatry 2002; 63: 241-244
46. Villeneuve E, Lemelin S. Open-label study of atypical neuroleptic quetiapine for treatment of borderline personality disorder: impulsivity as main target. J Clin Psychiatry 2005; 66: 1298-1303
47. Nickel MK, Muehlbacher M, Nickel C et al. Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry 2006; 163: 833-838
48. Kellner M. Aripiprazole in a therapy-resistant patient with borderline personality and post-traumatic stress disorder. Pharmacopsychiatry 2007; 40: 41
49. Mobascher A, Mobascher J, Schlemper V, Winterer G, Malevani J. Aripiprazole pharmacotherapy of borderline personality disorder. Pharmacopsychiatry 2006; 39: 111-112
50. Swann AC, Birnbaum D, Jagar AA, Dougherty DM, Moeller FG. Acute yohimbine increases laboratory-measured impulsivity in normal subjects. Biol Psychiatry 2005; 57: 1209-1211
51. Philipsen A, Richter H, Schmahl C et al. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004; 65: 1414-1419
52. Schmahl C, Stiglmayr C, Bohme R, Bohus M. [Treatment of dissociative symptoms in borderline patients with naltrexone]. Nervenarzt 1999; 70: 262-264
53. Zanarini MC, Frankenburg FR. omega-3 Fatty acid treatment of women with borderline personality disorder: a double-blind, placebo-controlled pilot study. Am J Psychiatry 2003; 160: 167-169
54. Faravelli C, Zucchi T, Viviani B et al. Epidemiology of social phobia: a clinical approach. Eur Psychiatry 2000; 15: 17-24
55. Davidson JR. Pharmacotherapy of social phobia. Acta Psychiatr Scand Suppl 2003; 417: 65-71
56. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005; 62: 190-198
57. Reich J, Noyes JrR, Troughton E. Dependent personality disorder associated with phobic avoidance in patients with panic disorder. Am J Psychiatry 1987; 144: 323-326
58. Baer L, Jenike MA, Ricciardi JN et al. Standardized assessment of personality disorders in obsessive-compulsive disorder. Arch Gen Psychiatry 1990; 47: 826-830
59. Zohar J, Insel TR. Obsessive-compulsive disorder: psychobiological approaches to diagnosis, treatment, and pathophysiology. Biol Psychiatry 1987; 22: 667-687
60. Ansseau M, Troisfontaines B, Papart P, Frenckell R von. Compulsive personality as predictor of response to serotoninergic antidepressants. BMJ 1991; 303: 760-761
61. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26: 151-154
62. Silva H, Jerez S, Paredes A et al. [Fluoxetine in the treatment of borderline personality disorder]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1997; 25: 391-395
63. Simpson EB, Yen S, Costello E et al. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 379-385
64. Ekselius L, Knorring L von. Personality disorder comorbidity with major depression and response to treatment with sertraline or citalopram. Int Clin Psychopharmacol 1998; 13: 205-211
65. Bogenschutz MP, George NH. Olanzapine versus placebo in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 104-109
66. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999; 46: 1429-1435
67. Szigethy EM, Schulz SC. Risperidone in comorbid borderline personality disorder and dysthymia. J Clin Psychopharmacol 1997; 17: 326-327
68. Pinto OC, Akiskal HS. Lamotrigine as a promising approach to borderline personality: an open case series without concurrent DSM-IV major mood disorder. J Affect Disord 1998; 51: 333-343
69. Tritt K, Nickel C, Lahmann C et al. Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol 2005; 19: 287-291
70. Kavoussi RJ, Coccaro EF. Divalproex sodium for impulsive aggressive behavior in patients with personality disorder. J Clin Psychiatry 1998; 59: 676-680
71. Hollander E, Swann AC, Coccaro EF, Jiang P, Smith TB. Impact of trait impulsivity and state aggression on divalproex versus placebo response in borderline personality disorder. Am J Psychiatry 2005; 162: 621-624
72. Roth AS, Ostroff RB, Hoffman RE. Naltrexone as a treatment for repetitive self-injurious behaviour: an open-label trial. J Clin Psychiatry 1996; 57: 233-237